The effect of hesperidin use on the clinical condition of patients with the new coronavirus

Investigating the effectiveness of the use of hesperidin on the clinical conditions of patients with the new coronavirus (SARS-COV-2)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150725023332N5

Enrollment

Registered

2021-04-06

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus not identified

Interventions

Intervention 1: Intervention group: Patients in this group, in addition to conventional treatment, receive 1 mg of hesperidin orally every 6 hours for 5 days. Intervention 2: control group: Patients i

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with new coronavirus who hospitalized in the intensive care unit

Exclusion criteria

Exclusion criteria: Patients with intubation conditions History of severe liver disease History of severe renal disease Patient dissatisfaction to participate in the project Age over 65 and under 18 years

Design outcomes

Primary

Measure	Time frame
Lactate dehydrogenase. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Lactate dehydrogenase testing by blood sampling.;Cratinin. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Testing for creatinine in the serum.;BUN. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Blood urea test.	—

Measure

Time frame

Lactate dehydrogenase. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Lactate dehydrogenase testing by blood sampling.;Cratinin. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Testing for creatinine in the serum.;BUN. Timepoint: Before prescribing of Hesperidin and 5 days after taking it. Method of measurement: Blood urea test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza jahangirifard

Shahid Beheshti University of Medical Sciences

Alirezajahangiri@sbmu.ac.ir+98 21 2712 2537

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026